We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use routinely collected data to evaluate your digital health product.
Why it's important to evaluate digital health products that have been developed rapidly and how to choose evaluation methods in these circumstances.
This guidance provides information on comparator products used in studies supporting abridged marketing authorisation applications
Attributions of risk and blame in smart product failure.
Case study from Armilla.
How to use a factorial randomised controlled trial to evaluate your digital health product.
Case study from Citadel.
Product Safety Report for PTS Packers and Providers Pvt Surfaz-SN Triple Action Cream presenting a serious chemical risk.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.